Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans

NCT ID: NCT05186636

Last Updated: 2025-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-12

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Providing acute dialysis to critically ill patients in ICU settings is resource and cost intensive. The daily costs of acute dialysis can range from $528/day for intermittent hemodialysis to $865/day for continuous renal replacement therapy. Providing acute dialysis in ICU settings requires a specialized team of nurses, educators, physicians and stakeholders to ensure its safe and effective prescription and delivery. Acute dialysis is typically delivered to some of the most acutely ill patients admitted to the ICU to support organ function and sustain life.

At present, there is not a standardized approach to the prescription and delivery of acute dialysis therapy in ICUs across Alberta. The DIALYZING WISELY program will implement a standardized approach to the delivery of best practices for acute dialysis therapy to all patients who receive treatment across ICUs in Alberta.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Renal Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICU patients receiving renal replacement therapy

All patients in participating ICU's receiving CRRT or IRRT during the study period

KPI reports

Intervention Type OTHER

Quarterly

Prescriber reports

Intervention Type OTHER

Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KPI reports

Quarterly

Intervention Type OTHER

Prescriber reports

Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Monitoring, reporting and regular review of acute RRT KPIs

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient in one of 15 adult and 3 pediatric intensive care units in Alberta Receive acute RRT as part of their usual clinical care during the intervention period

Exclusion Criteria

* none
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alberta Innovates Health Solutions

OTHER

Sponsor Role collaborator

University of Alberta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Oleksa Rewa, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peter Lougheed Centre

Calgary, Alberta, Canada

Site Status RECRUITING

Foothills Medical Centre

Calgary, Alberta, Canada

Site Status RECRUITING

Rockyview General Hospital

Calgary, Alberta, Canada

Site Status RECRUITING

Alberta Children's Hospital

Calgary, Alberta, Canada

Site Status RECRUITING

South Health Campus

Calgary, Alberta, Canada

Site Status RECRUITING

Royal Alexandra Hospital

Edmonton, Alberta, Canada

Site Status RECRUITING

Misericordia Community Hospital

Edmonton, Alberta, Canada

Site Status RECRUITING

Manzankowski Alberta Heart Institute

Edmonton, Alberta, Canada

Site Status RECRUITING

Stollery Children's Hospital

Edmonton, Alberta, Canada

Site Status RECRUITING

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status RECRUITING

Grey Nuns Community Hospital

Edmonton, Alberta, Canada

Site Status RECRUITING

Grande Prairie Regional Hospital

Grande Prairie, Alberta, Canada

Site Status RECRUITING

Chinook Regional Hospital

Lethbridge, Alberta, Canada

Site Status RECRUITING

Red Deer Regional Hospital Centre

Red Deer, Alberta, Canada

Site Status RECRUITING

Sturgeon Community Hospital

St. Albert, Alberta, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dawn Opgenorth, RN

Role: CONTACT

780 492-4698

Oleksa Rewa, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

Oleksa Rewa, MD

Role: primary

780-231-3280

References

Explore related publications, articles, or registry entries linked to this study.

Opgenorth D, Bagshaw SM, Lau V, Graham MM, Fraser N, Klarenbach S, Morrin L, Norris C, Pannu N, Sinnadurai S, Valaire S, Wang X, Rewa OG. A study protocol for improving the delivery of acute kidney replacement therapy (KRT) to critically ill patients in Alberta - DIALYZING WISELY. BMC Nephrol. 2022 Nov 16;23(1):369. doi: 10.1186/s12882-022-02990-6.

Reference Type DERIVED
PMID: 36384465 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00112499

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.